Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Epithelial to Mesenchymal Transition in Lethal Forms of Cancer and Fibrotic Disease

Epithelial to Mesenchymal Transition in Lethal Forms of Cancer and Fibrotic Disease

Facebook0
Google+0
LinkedIn3
Twitter0
By John Leavitt, Ph.D., Nerac Analyst,
Originally Published: February 17th, 2015

The emergence of the role of “Epithelial to Mesenchymal Transition” (EMT) is the most important development in cancer research since the discovery of oncogenes in the 1980’s. Tumor cell EMT provides a mechanism for acquiring chemo-resistance of tumors and metastasis that has only recently been appreciated by companies developing anti-cancer and anti-fibrosis diagnostics and drugs.

Want to read the rest of the article? Fill out the form to download: Epithelial to Mesenchymal Transition in Lethal Forms of Cancer and Fibrotic Disease
Get Download Link

 

 

 

 

Related Posts

  • A Glimpse into the Vital Core of Tumor Cell Development
    52
    By John Leavitt, Ph.D. Nerac Analyst Originally Published: August 12, 2014 In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt…
    Tags: leavitt, published, tumors, read, ph.d, analyst, john, tumor, originally, nerac
  • Nerac Announces Addition to Analyst Team
    32
    New analyst brings extensive experience in engineering, energy and environmental systems Read the full release here.
    Tags: analyst, read, full, originally, published, nerac
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies emerging markets energy EU MDR FDA food Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • Linkedin
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities

Copyright © 2021 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.